On July 11 ASIT biotech raised €12m in commitments in a heavily oversubscribed convertible bond placement. In raising this additional capital, ASIT outlined the primary use of the proceeds which is to fund the Phase III study of its short-course grass pollen allergy immunotherapy (AIT) product gp-ASIT+. An update was provided on its earlier-stage products – house dust mite and peanut allergy AITs. We speculated on the latter in our initiation note and it is now confirmed.
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
ASIT Biotech - All go on Phase III
On July 11 ASIT biotech raised €12m in commitments in a heavily oversubscribed convertible bond placement. In raising this additional capital, ASIT outlined the primary use of the proceeds which is to fund the Phase III study of its short-course grass pollen allergy immunotherapy (AIT) product gp-ASIT+. An update was provided on its earlier-stage products – house dust mite and peanut allergy AITs. We speculated on the latter in our initiation note and it is now confirmed.